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Antibody drug conjugates (ADCs) are emerging therapeutic products specially 
designed for the treatment of cancers. Potent cytotoxic agents are linked to antibodies via 
linkers. Antibody drug conjugates, which take advantage of both antibodies and cytotoxic 
agents, showed high selectivity towards cancer cells. Cytotoxic agents are delivered to the 
cancer cells selectively and kill them from inside while leaving low or non-toxicity towards 
normal cells. Antibody drug conjugates are actually heterogeneous mixtures. The major 
heterogeneities mainly lie in the drug to antibody ratio (DAR) and drug linking positions, 
both of which potentially affect the therapeutic index of ADCs. In this research, we focused 
on the interchain cysteine linked ADCs, which are the most popular class. We first 
developed methods and characterized the drug linking position heterogeneity. Positional 
isomers of interchain cysteine linked ADCs were separated and their relative abundance 
was determined. In addition, novel LC/HRMS methods were developed for the accurate 
determination of the DAR with cleavable and non-cleavable linkers.  Meanwhile, we also 
designed and synthesized new ADCs, namely Cetuximab-Staurosporine for EGFR over 
expressed Non-Small Cell Lung Cancer. The anticancer effects were evaluated on A549 
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1.1. CANCER AND CHEMOTHERAPY 
Cancer is a major public health problem worldwide and is the second leading cause 
of death in the United States.1 In the past year, 1,762,450 people were diagnosed with 
cancer and 606,880 patients died in United States.1 The overall survival rate was quite low, 
with some cancer as low as less than 20%. Surgery that removed tumor was desired the 
treatment method for cancer. However, many of the cancers were diagnosed in later stages 
where the use of surgery was limited. Instead, chemotherapeutic agents such as DNA 
damaging agents, tubulin inhibitors and antifloate agents were applied for treatment.2-4 
Chemotherapeutic agents usually lack specificity to tumor cells with their selectivity 
relying on the relatively higher uptake rate of rapidly growing cancer cells than that of 
normal cells.3 In addition to the disadvantage that many patients developed acquired 
resistance to the chemotherapeutic agents, one significant drawback of those agents were 
their toxicities to normal tissues, especially normal tissues characterized with enhanced 
proliferation rate.3-4  Medicinal chemists and oncologists have long sought ways to increase 
the delivery of cytotoxic chemicals to cancer cells for increased efficacy, while minimizing 
the exposure of normal healthy tissue.5-6 
1.2. ANTIBODY DRUG CONJUGATES 
Antibody drug conjugates are emerging target therapeutic products specially 
designed for cancer treatment. The concept of antibody drug conjugates can be dated back 




Antibody drug conjugates are sophisticated drug delivery systems that deliver anticancer 
agents to the cancer cells selectively.8  An ADC consists of three components: monoclonal 
antibody (mAb), linker and cytotoxic agent (Figure 1.1).9 The cytotoxic agent is linked to 
the surface of the antibody by a linker, which forms covalent bonds at both ends with 
functional groups on the antibody and cytotoxic agents. Monoclonal antibodies that govern 
selectivity act as the drug carrier to deliver the cytotoxic agent to the tumor cells where the 
cytotoxic agents take action, which trigger cell apoptosis.9-10   
 
 
Figure 1.1. Structure of antibody drug conjugates. 
 
Antibody drug conjugates take advantages of both antibody and cytotoxic agents, 
greatly enhancing the selectivity and lowering systematic toxicity toward health cells.11 
Antibody drug conjugates were promising target therapeutics for the treatment of cancers. 




1.2.1. Antibody.  Antibodies, also known as immunoglobulins, are big biological 
proteins mainly produced in plasma B cells and are important components of the immune 
system. There are five types of immunoglobulins in human beings, namely IgM, Ig D, Ig 
G, Ig A and Ig E. These immunoglobulins are close related glycoprotein with the exception 
of the heavy chain structure and effectors function. Among these immunoglobulins, IgG 
accounts for about 80% of the total immunoglobulin and is the most abundant 
immunoglobulin in blood. IgG can be further divided to four subclasses in order of 
decreasing abundance: IgG1, IgG2, IgG3 and IgG4. As a major component of IgG and is 
responsive to membrane proteins, IgG1 has attracted a lot of attention for developing 
antibody drug conjugates. In ADCs, the antibodies were almost exclusively IgG1. 
 
 






As shown in Figure 1.2, IgG1 is a Y shaped glycoprotein molecule with a MW of 
about 150 K Da. It has two light chains and two heavy chains with length of roughly 210 
and 450 amino acids, respectively. In IgG1, there are two glycans attached on the 
asparagine residues located at the CH2 region of the Fc domain,12 it has folded structure 
under native condition where the hydrophobic fragments are buried inside while the 
hydrophilic fragments are exposed outside. This makes IgG1 a good aqueous soluble 
molecule. IgG1 also has 16 pairs of interchain disulfide bonds, which are buried inside of 
the folded structure and are not solvent accessible under native condition. It also contains 
four pairs of interchain disulfide bonds, two of which are between light chain and heavy 
chain while the other two are located in the hinge region between the heavy chains.  
 




RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ 
WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 
KHKVYACEVT HQGLSSPVTK SFNRGEC 
Lambda Light 
Chain Constant 
GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK 





ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS 
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG 
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW 
YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK 
EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE 
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 





Structurally, IgG1 consists of one variable region and three constant regions. The 
variable region is located at the top of two arms. It consists of VL and CL, which interact 
with each other and form three complementarity-determining regions that determine the 
specificity of the antibody. The unique structure at the end of the variable region was the 
antigen binding site where the antibody binds to antigen and forms a complex. IgG1 also 
contains several constant regions, namely CL and CH1-3. Compared to the variable region, 
the constant regions were universal to all the IgG1, and their sequence and structure were 
kept constant regardless of the variation in the variable region. IgG1 has a single type of 
heavy chain and two types of light chains, which are Kappa or Lambda.  Their amino acid 
sequences of the constant region were shown in Table 1.1.   
1.2.2. Linker.  Linker is a vital component that impacts the effectiveness of 
ADCs.13 Structurally, linker acts as a bridge that joins the antibody and anticancer agents 
together. It has active functional groups on both ends and is capable of reacting with 
functional groups of both antibody and anticancer agents. Linkers need to possess two key 
attributes: stability during circulation and drug release after internalization.6, 14 Linkers 
should be sufficiently stable enough to maintain the cytotoxic agents attached on the 
antibody to provide extended circulation time, and to enhance drug localization to cancer 
cells. Meanwhile, linkers should prevent the premature release of cytotoxic agents, which 
usually lack selectivity, are harmful to healthy cells, and lower the therapeutic efficacy.6 
After internalization, the ADCs should efficiently release the active drugs to change ADCs 
from pro-drugs to active drugs.15 The form of active drug varies depending on the linker 
types. Linkers can be characterized as cleavable linkers (Figure 1.3), which are susceptible 




agents,16-19 or as non-cleavable linkers (Figure 1.3), which rely on the complete digestion 
of the antibody backbone to release the payload linked with the amino acid that it is 
attached to.20-21   
 
 
Figure 1.3. Non-cleavable and cleavable linkers. 
 
In addition, the hydrophobicity of the payload, which is partly due to the linker, is 
also an important factor that affect the efficacy of ADCs.22  The payload of ADCs is usually 
hydrophobic, and linking of payload to the antibody adds additional hydrophobicity to the 
antibody.23 This may induce aggregation, which has been linked to increased 
immunogenicity and hepatotoxicity.23-24 Meanwhile, the hydrophobic nature of the payload 
makes it a good target for multidrug resistant transporters.23 It has been reported that a 
hydrophilic linker enhanced the effectiveness of DM1, a hydrophobic anticancer agent.25   
1.2.3. Cytotoxic Agents.  Unlike traditional chemotherapy drugs, the cytotoxic 




concentrations considering the number of antigens expressed on the tumor cell surface and 
the fact that limited anticancer agents can be linked on antibody without severely 
compromising the physical and pharmacokinetics of ADCs.14, 26 The cytotoxic agents used 
in ADCs have toxicities that are usually at nM or pM level.26-27    
 
 
Figure 1.4. Cytotoxic agents of ADCs. 
 
Current cytotoxic agents employed in ADCs are usually derivatives of 
calicheamicin (Figure 1.4), which kill cells by interacting with DNA and introducing DNA 
double strand breaks to trigger cell apoptosis.14, 28 They also may be derivatives of 
dolastatin 10 and maytansine (Figure 1.4), a family of antimitotic microtubule disrupting 
agents that inhibit the cell mitosis and trigger cell apoptosis.27, 29-31   
1.3. MECHANISM OF ACTION OF ADCS 
The mechanism of action of ADCs involves in several steps, which are depict in 




cells with expressed antigens on their surfaces.  The ADCs recognize the antigen, or more 
specifically the epitope on the antigen, and bind to it tightly, forming an ADC/antigen 
complex. The complex then undergoes a process called internalization via receptor-
mediated endocytosis.  
 
 
Figure 1.5. Action mechanism of antibody drug conjugates. 
 
The internalized ADCs are subsequently transferred to late endosome and form 
lysosome, which has an acidic environment and contains multiple enzymes. The following 
protease digestion transferred the ADCs from the pro-drug form to active drug form by 
digesting the linker or peptide back bone, depending on the linker types.  The active drugs 
that are released into the cytoplasm bind to specific organelles or structures, usually DNA 




ADCs are sophisticated drug delivery systems specially designed to deliver the cytotoxic 
drugs to cancer cells and kill them, while leaving normal cells mostly unaffected.   
1.4. ADC CLASSIFICATION 
Antibodies are large protein molecules that maintain folded structure under native 
conditions. That structure plays a critical role in the functioning of ADCs. Therefore, 
antibodies cannot be denatured during drug conjugation, so limited functional groups can 
be used for payload conjugation, considering the available functional groups on the surface 
of the antibody. ADCs can be divided into three classes based on the drug linking methods. 
Figure 1.6 displays the three types of ADCs, namely lysine linked ADCs, interchain 
cysteine linked ADCs, and engineered cysteine linked ADCs.32  
In lysine linked ADCs, payload is linked on the lysine, more specifically, the amine 
group located at the end of the side chain.23, 33 Human IgG1 mAb contains about 16 lysines 
on the surface of the antibody, which are solvent accessible and therefore may be linked 
with payloads. In addition to lysine, cysteine linking was another popular method. Human 
IgG1 contains four pairs of interchain disulfide bonds, which are not very important for the 
stability of the antibody. In interchain cysteine linked ADCs, the payloads are linked on 
the interchain cysteine, taking advantage of the click chemistry between maleimide and 
thiol. The reduction of a disulfide bond generates two free thiols, which may be linked with 
two payloads.34 Even though the four pairs of interchain disulfide bonds are not very 
important for the stability of the antibody, disruption of those disulfide bonds potentially 
lowers the stability of the antibody.35 Instead of employing native cysteine, the engineered 




during manufacturing.36 The payloads are linked on the inserted cysteines, and the native 
disulfide bonds are not disturbed.34 Among all these ADCs, interchain cysteine linked 
ADCs are the most popular one due to their relatively narrow drug to antibody ratio (DAR) 
distribution and good therapeutic index.  
 
 
Figure 1.6. Antibody drug conjugation classification. 
 
1.5. ADC MANUFACTURE  
Manufacture of the interchain cysteine linked ADCs requires several steps as shown 
in Figure 1.7. In human IgG1, all interchain cysteines are paired and there have no free 
thiols for drug conjugation. Therefore, the interchain disulfide bonds need to be reduced to 
active thiol before conjugation. Limited amounts of DTT or TCEP are added to the 




Afterwards, the excessive DTT or TCEP is removed. Payloads that composed of linkers 
and drugs are added to the reduced antibodies for conjugation. The maleimide moiety of 
the payload reacts readily with the thiol and forms stable a covalent bond. As a 
consequence, the payload was firmly linked on the antibody.  
 
 
Figure 1.7. Manufacture of interchain cysteine linked ADCs. 
 
Reduction of one disulfide bond generates two free thiols and therefore can be 
linked with two payloads. Depending on the random reduction of the interchain disulfide 
bonds, the antibody might be linked with 0, 2, 4, 6 or 8 payloads.37  
1.6. ADCS HETEROGENEITY 
The heterogeneity of the interchain cysteine linked ADCs mainly lies on drug 
linking numbers and drug linking positions.34, 38 In the manufacturing process, the 
interchain disulfide bonds of the antibody are randomly reduced, and therefore the antibody 
might be linked with 0, 2, 4, 6, or 8 drugs (Figure 1.8) depending on the reduction of the 





Figure 1.8. Heterogeneity of interchain cysteine linked antibody drug conjugates. 
 
It is obvious that the number of cytotoxic drugs linked on antibody is proportional 
to the number of drugs delivered to the cancer cells, and therefore the drug linking number 
is a vital parameter directly affecting the therapeutic efficacy.39 Theoretically, the more 
drug linking on the antibody, the better therapeutic effect would be expected. However, the 
drug linking number also affects the therapeutic effects by its impact on the hydrophobicity 
of the ADCs.22 The payloads employed in ADCs are usually hydrophobic, and therefore 
linking of payloads to the antibody increased the hydrophobicity of the antibody. This tends 
to cause the ADCs to aggregate, while the aggregation not only decreases the efficacy of 
the ADCs but also increases the risk of hepatotoxicity.23-24 In a clinical trial of an interchain 
cysteine linked ADCs, ADCs with an average drug number of 4 showed similar therapeutic 




of ADCs linked with more drugs.40 The drug linking number is a critical factor that affect 
the efficacy of the ADCs in multiple ways.  
In addition to the drug linking number, the drug linking position is another major 
heterogenity. Even though the same number of drugs are linked on the antibodies, the drugs 
linking positions might be different (Figure 1.8). Drug linking positions might potentially 
affects the stability of the ADCs and therefore influence the therapeutic efficacy.41 In 
interchain cysteine linked ADCs, the conjugation is via maleimide-thiol reaction. 
However, the reaction is reversible even though the reverse reaction rate is very low. 
Human blood contains plenty of albumin (contains one active thiol) and other free active 
thiols. The active thiols compete with the antibody for drugs.42 In a clinical trial, it was 
found the drug was transferred to albumin, which indicated the deconjugation of the 
payload from antibody.42 Drug deconjugation not only reduced the potency of the ADCs, 
but also enhanced the off-target toxicity since the deconjugated drug doesn’t have 
selectivity.43 Baldwin et al. investigated the conjugation stability of the maleimide and thiol 
reaction and found that the reactivity of the thiol is related to the stability of the 
conjugation.44 Later, Shen and coworkers found that the deconjugation of the drug from 
the antibody was largely affected by the solvent accessibility.45 The more water accessible 
the linking position is, the more easy it is to cause drug deconjugation.45 Difference of drug 
linking positions actually potentially affects the therapeutic efficacy. 
1.7. ADC CHARACTERIZATIONS 
The characterization of interchain cysteine linked ADCs is challenging. The 




susceptible to acid and organic solvents. Antibody drug conjugates are easily denatured by 
any harsh conditions, which makes the characterization more difficult. Hydrophobic 
interaction chromatography (HIC) – UV/Vis that operates under non-denaturing condition 
is a good choice for characterization.46-47 Different DAR species can be separated and the 
drug number can be determined by extinction coefficient of antibody and payload. 
However, HIC is not compatible with mass spectrometer and therefore unable to confirm 
the mass of each species. In recent years, high resolution mass spectrometry (HRMS) has 
become popular technique for the characterization of interchain cysteine linked ADCs.48-
50 The ADCs may be characterized by HRMS in three ways, as shown in Figure 1.9, namely 
top down, middle down and bottom up.51   
In top down characterization, ADCs are directly analyzed by HRMS under non-
denaturing conditions in which the ADCs still maintain an intact structure.52 The raw mass 
spectra of the ADCs contains several species with multiple charge states. It is difficult to 
directly interpret the mass spectra. Instead, the raw mass spectra is processed with software 
to obtain the deconvoluted mass spectra, in which same species with different charge states 
are deconvoluted to one peak displaying the molecular weight. HRMS is effective to 
differentiate different DAR species, but it fails to provide any drug linking position 
information. Size exclusion chromatography (SEC) using volatile salts are compatible with 
HRMS and can be used for separation. However, the mass differences between different 
species are limited, usually 1-3 KDa. The differences are too small to achieve full 
separation considering the large molecular weights of intact ADCs which are about 150 K 






Figure 1.9. Top down, middle down and bottom up characterization of ADCs. 
 
Middle down is another popular characterization method. It is similar to the top 
down method but has some differences in the sample preparation. In middle down 
characterization, the ADCs are digested to relatively shorter fragments that contain more 
information regarding the drug linking positions and drug distribution.49 Unlike top down 
method, the middle down method is compatible with denaturing condition, therefore RPLC 
may be used for separation of different species. Even though it is hard to fully separate all 
the fragments, the middle method is still able to provide plenty of information regarding 




In bottom up method, the ADCs are digested by enzymes, usually trypsin, 
chymotrypsin or Glu-C, into short peptides that have mass ranging from hundreds to 
thousands Da. The short peptides contain more detailed information regarding drug linking 
positions, modifications on the backbone of the ADCs.54 The combination of RPLC and 
HRMS makes the bottom up strategy a powerful method to provide more detailed 
information regarding minor modifications on the ADCs. Meanwhile, when standard is 
employed, the bottom up analysis of ADCs is extended from qualitative analysis to 
quantitative analysis, which greatly supports the characterization of ADCs.55  
1.8. DRUG TO ANTIBODY RATIO DETERMINATION 
Drug to antibody ratio is a vital factor of the ADCs and therefore needs to be 
accurately determined. HIC-UV/Vis or UV/Vis methods are considered gold standard 
methods for the measurement of DAR.46, 52 The DAR can be calculated based on the 
abundance of each DAR species or the extinction coefficient of antibody and payload.40 
However, these methods require large amounts of samples and high ADC concentration 
because of the low sensitivity of UV/Vis detectors. Meanwhile, those methods are easily 
affected by matrix and therefore usually not applicable to clinical samples. Recently, high 
resolution mass spectrometry (HRMS) has attracted lot of attention for DAR 
determination. HRMS analysis of the ADCs at intact or subunit level provides a feasible 
way to determine the DAR.48, 56 However, the DAR is a rough estimation rather than a 
accurate determination.  
In HRMS analysis, the DAR is calculated based on the abundance of each species 




However, high DAR species have relatively lower ionization efficiency and therefore 
results in lower mass response. Chen et al. compared the DAR calculated by HIC-UV/Vis 
and HRMS as shown in Table 1.2.52 The abundances of high DAR species in HRMS 
analysis were much lower than those in HIC-UV/Vis analysis.52  Accurate determination 
of DAR by HRMS is still challenging due to the ionization efficiency variations of different 
DAR species. 
 
Table 1.2. DAR profile of Native HRMS and HIC of interchain cysteine linked ADCs. 
 
1.9. NON-SMALL CELL LUNG CANCER  
Lung cancers are the leading causes of cancer related death in the United States. It 
is estimated that there are 234,000 new cases and 154, 000 deaths per year.57 Despite the 
new therapies that has been developed in recent years, the 5-year survival rate is very low 
only 18%.58 Among lung cancers, non-small cell lung cancers (NSCLC) was a major type 
that accounts for 85% of the lung cancers.59 Several therapies were developed for the 
treatment of NSCLC. Surgery that removed the tumor was the most desired therapy. 
However, more than half of the NSCLC patients were diagnosed at advanced stage or 




the dominant treatment therapy.59-60 However, chemotherapy was frequently associated 
with drug resistance where cancer cells developed acquired resistance to the chemotherapy 
drugs.61-62 Meanwhile, severe side effects were observed in almost all patients receiving 
chemotherapy due to the non-selectivity of the chemotherapy drugs.63 While killing the 
cancer cells, many healthy cells were also affected.  Actually, chemotherapies only showed 
modest survival benefits during the late stage lung cancer treatment.64-65 Developing target 
therapies is in high demand for the treatment of NSCLC to overcome the disadvantages of 
the chemotherapy. 
EGFR is a transmembrane protein expressed on the surface of cells.66 It has been 
associated with tumor proliferation, metastasis and suppression of apoptosis.67 It has a low 
level of expression in normal tissue,68 but, there has been abnormally high expression of 
EGFR in some NSCLC patients.69 Approximately 25% of the lung cancer patients were 
detected with over expressed EGFR in tumor cells (IHC score ≥300).69 The large difference 
in EGFR expression between normal cells and tumor cells made it a good target for 
specially targeting lung cancer cells that have over-expressed EGFR.  
1.10. CETUXIMAB 
Cetuximab is a mouse/human chimerical IgG1 antibody developed in the late 
1990s. Similar to human IgG1, the constant region of the Cetuximab is the same as human 
IgG1. However, the variable region of the Cetuximab is specially developed, which can 
specially recognize and bind to the extracellular domain of EGFR (Figure 1.10 A).70  
Cetuximab binds the EGFR at the EGF binding site and therefore competes with 




clinical trials.71 Despite its poor therapeutic effects, Cetuximab has high affinity to both 
wild type and EGFRVIII mutated EGFR, and the Kd is only 0.38 nM.72 It seems promising 
to employ Cetuximab to specially targeting the EGFR overexpressed NSCLC. 
 
 
Figure 1.10. Structure of Cetuximab, EGFR, EGF and Staurosporine.  
(A) Variable region of Cetuximab interact with EGFR. (B) Structure of Staurosporine. 
1.11. STAUROSPORINE 
Since discovered in 1982, Staurosporine (STS, Figure 1.10B) has attracted a lot of 
attention for the treatment of cancers.73-74 However, its poor selectivity has limited its 
application in pharmaceutical application.75 STS has very high affinity toward cyclin 
dependent kinase 2 (CDK2), an important protein involved in cell division cycle, and the 
IC50 is only 3.2 nM.76-77 STS binds to the CDK2 at the ATP binding site and mimics 
the hydrogen bonds made by the adenine moiety of ATP. After binding to CDK2, the 
moieties of STS form several hydrogen bonds with Glu 81, Leu 83, Asp 86 and Gln131, 




environment that has poor solvent accessibility, which inhibits the binding of ATP to 
CDK2. Thus, the function of CDK2 is inhibited and it fails to phosphorylate downstream 
proteins. Therefore cells are arrested at the end of G1 phase or G2 phase.78 Incubation of 
A549 lung cancer cells with 4 nM STS for 2 days induced about 50% of the cell growth 
inhibition.79  Cells were found to be arrested at G1 and G2/M phases, and cell apoptosis 
was observed.79-80 It was found that STS induced two Casp 3 dependent and one Casp 3 
independent pathways of apoptosis.81-82 STS is an interesting compound that kills cancer 
cells by inducing cell division inhibition. However, additional methods to increase the 
selectivity toward cancer cells are required. 
1.12. CETUXIMAB-STAUROSPORINE 
Cetuximab-Staurosporine (Figure 1.11) that possesses the advantages of both 
Cetuximab and Staurosporine seems to be a very promising anticancer drugs for the 
treatment of EGFR over expressed NSCLC.  
 
 




The antibody portion is expected to selectively recognize and bind to the EGFR 
over expressed cancer cell, and further deliver the toxic STS into the cancer cells. The STS 
would bind to the CDK2 and inhibit its function. The cells would be expected to be arrested 
at G1 and G2 phase and further induce apoptosis. Cetuximab-Staurosporine would be 
interesting ADCs and it would be worthful to investigate its effectiveness the on treatment 
of EGFR overexpressed NSCLC. 
1.13. RESEARCH OBJECTIVE 
This work aims to develop analytical method for characterization and drug to 
antibody determination of interchain cysteine linked ADCs, as well as design, synthesis 
and anticancer effectiveness investigation of ADCs. The whole work including three 
parts:  
(1) Characterization of positional isomers of interchain cysteine linked ADCs. 
Subunit analysis and bottom up analysis were combined to analyze the drug distribution, 
separate positional isomers and identify drug linking positions. 
(2) Accurate determination of drug to antibody ratio of interchain cysteine 
linked ADCs with cleavable or non-cleavable linkers.  
(3) Design, synthesis and anticancer effectiveness investigation of ADCs. 
New ADCs, Cetuximab-Staurosporine, were synthesized and characterized. The 
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ABSTRACT 
Interchain cysteine linked antibody drug conjugates (ADCs) are emerging 
therapeutic products that antagonize with cancers. The toxic payloads are selectively linked 
to the interchain cysteines but generate heterogeneous mixtures of positional isomers. 
These positional isomers might contribute differently to the therapeutic efficacy due to the 
variation of conjugation stability and thus need to be well characterized. However, the 
characterization of the positional isomers of interchain cysteine linked ADCs is very 
challenging mainly due to the high similarity between those isomers. In this research, we 
developed a novel mass spectrometry method for characterization of positional isomers of 
interchain cysteine linked ADCs. The subunit analysis and the bottom-up analysis provided 
abundant information about the drug numbers and drug linking positions on each chain. 









Antibody drug conjugates (ADCs) are novel therapeutic products that combine 
monoclonal antibodies (mAb) and cytotoxic small molecules for treatment of cancers[1]. 
The toxic drug molecules were linked to lysine or cysteine on the mAb via a cleavable or 
non-cleavable linker[2]. The conjugates can target specific cancer cells and greatly enhance 
the selectivity of the drug molecules (cytotoxic payload) while maintaining other cells 




trastuzumab emtansine greatly inspired pharmaceutical companies to develop new ADC 
products[4]. Currently, there are more than 65 ADCs that antagonize with cancers are under 
clinical trials and more are under pre-clinical developments[5, 6]. Among these ADCs, 
about two-third of them are interchain cysteine linked ADCs based on the disclosed 
information[7]. The interchain cysteine linked ADCs are manufactured by partial reduction 
of the 4-pair interchain disulfide bonds which are not very important for the stability of the 
antibody, followed by alkylation of  reduced sulfhydryl function group with maleimide 
linker that connected with cytotoxic drug at the other end[8, 9]. Depending on the reduction 
of the interchain disulfide bonds, the antibody may be linked with 0, 2, 4, 6 and 8 drugs 
and usually with average of 4 drugs/antibody considering the hydrophobicity increments 
of the drug loading. Conjugation of drug molecules to the antibody increased the structural 
complexity and thus requires comprehensive characterization of the ADCs. 
Current methods for characterization of interchain cysteine-linked ADCs mainly 
focus on the drug to antibody ratio (DAR) and drug distribution,[10-12] size and charge 
variants,[13, 14] and biophysical properties.[15, 16] Little attention is paid on the 
positional isomers. Even though the thiol-maleimide conjugation is stable under in vitro 
environment, deconjugation often happens in vivo due to the thiol exchange with reactive 
thiols of the albumin, free cysteine and glutathione[17, 18]. Aaron D. Baldwin† and Kristi 
L. Kiick investigated the stability of thiol-maleimide in the presence of glutathione and 
found that the thiol-maleimide conjugation stability is strongly related with the reactivity 
of thiol group[19]. The reactivity of the thiols on antibody is mainly affected by the amino 
acid sequence and the functional groups near the thiol group, which indicates that the 




by Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu 
SF, Mai E et al demonstrated that the deconjugation of  maleimide from thiol was closely 
related to the linking positions[18].The drug was much easier to be deconjugated at solvent 
accessible linking positions comparing to those of relatively not solvent accessible 
positions.[18] Drug deconjugation during circulation reduced the potency of ADCs which 
partly depend on the extent of drug  linkage on mAb.[20, 21] Meanwhile, systemic 
exposure of the deconjugated drug might adversely affect the safety of the ADCs due to 
the non-selectivity of the deconjugated drug.[20, 22] 
Characterization of positional isomers of interchain cysteine linked ADCs is very 
challenging mainly due to the structural similarities. Direct analysis of ADCs at intact 
levels using multi-dimensional liquid chromatography UV mass spectrometry (LC-
UV/MS) has been developed for separation of different DAR species[23, 24]. However, 
the method was not sufficient to separate all the positional isomer of same DAR species. 
Even though chromatography separation of reduced ADCs can separate light chain (LC) 
and heavy chain (HC) with different drug-linked species, it is not able to separate all of the 
HC + 1 drug and HC + 2 drugs positional isomers[9, 25]. It was reported that treatment of 
ADCs with IdeS to remove the Fc portion can improve the separation of positional 
isomers[25, 26], but the HC + 1 drug and HC + 2 drugs positional isomers still cannot be 
fully separated. In this research, we developed a novel mass spectrometry method, as 
shown in Figure 1, for characterization of positional isomers of interchain cysteine linked 
ADCs, which provides important information regarding drug number and linking position 
on each chain by combining ADCs subunit analysis with the bottom-up analysis. The LC 




This novel analytical method will be very useful for cancer drug discovery, development 
and cancer treatment. 
 
 
Figure 1. The schematic showing of characterization of positional isomers of interchain 
cysteine linked ADCs. 
2. EXPERIMENTAL SECTIONS 
2.1. RAGENTS AND MATERIALS 
The deionized water was generated using a Millipore water purification system 




formic acid, acetonitrile (ACN) were obtained from Fisher Scientific (Fair Lawn, NJ); tris 
(2-carboxyethyl) phosphine (TCEP) was purchased from Thermo Fisher Scientific 
(Rockford, IL), and 1.0 M tris buffers (pH 7.4 and 8.0) were obtained from Invitrogen 
(Austin, TX). IdeS, PNGase F (10,000 unit/mL), trypsin and chymotrypsin were purchased 
from Promega Corporation (Madison, WI). Urea, Iodoacetamide, CaCl2 and ADCs (mAb-
SMCC-LC-Dansyl) were obtained from sigma Aldrich (St. Louis, MO). 
2.2. ADC DEGLYCOSYLATION 
ADCs were deglycosylated under non-denatured condition. Briefly, 4 µL of ADCs 
solution containing 20 µg of ADCs and 2 µL of the PNGase F solution were added to 14 
µL of 50 mM tris buffer (pH 7.4). The mixture was incubated overnight at 37 ᵒC. 
2.3. IDES DIGESTION 
Briefly, 4 µL of ADCs solution containing 20 µg of ADCs and 2 µL of IdeS enzyme 
solution containing 20 unit of IdeS were added to 34 µL of 50 mM tris buffer (pH 7.4). The 
mixture was incubated at 37 ᵒC for 1.0 hour. 
2.4. ADC SUBUNIT ANALYSIS 
Prior to mass spectroscopy analysis, the deglycosylated or IdeS digested ADCs 
were treated with 5 mM TCEP for 30 min for reduction. Afterwards, 1 µg of the reduced 
ADCs was injected onto column for separation (Waters XBridge protein BEH C4, 3.5 µm, 
2.1 x 50 mm, 300 Å). A Shimadzu LC-30 system employing deionized water containing 
0.1% formic acid as mobile phase A and ACN containing 0.1% formic acid as mobile phase 




isocratic elution with 5% mobile phase B was used for online desalting. The analytes were 
then eluted from column using 70% mobile phase B. The LC system was coupled with AB 
Sciex 6600 (QTOF) high resolution mass spectrometer (HRMS) operating in positive mode 
with ion spray voltage of 5000 V and temperature of 500 ᵒC. Acquisitions were performed 
on mass rang of m/z 800-4000 with 1.0 s accumulation time and bin of 40.  
2.5. DRUG LINKING PEPTIDES SEPARATION 
The IdeS treated ADCs were denatured by 6.0 M urea under 37 ᵒC for 1.0 hour in 
the presence of 5.0 mM TCEP for reduction. Then, 25.0 mM of iodoacetamide was added 
for alkylation over 30 min in the dark. Prior to chymotrypsin digestion, the sample was 
diluted with digestion buffer (50 mM tris with 10% ACN and 10 mM CaCl2, pH 8.0) to 
make urea concentration be less than 1.0 M. Chymotrypsin was then added as 1/50 
(enzyme/substrate) ratio to the mixture and the digestion was performed overnight at 25 
ᵒC. Formic acid was added up to 0.5% to quench the digestion.  
The digest was loaded onto a Waters ACQUITY BEH C18 column (1.7 µm, 2.1 x 
50 mm, 130 Å) that was heated at 50 ᵒC. The peptides were separated by a Shimadzu LC30 
system. Mobile phase A was water containing 0.1% formic acid and mobile phase B was 
ACN containing 0.1% formic acid. The flow rate was controlled at 0.3mL/min. 2.0 min 
isocratic elution with 5% mobile phase B was applied for desalting and then the peptides 
were eluted from column by increasing mobile phase B to 50% within 10.0 min. An AB 
Sciex 6600 QTOF HRMS equipped with ESI ionization source was used for data 




2.6. DRUG LINKING POSITIONS IDENTIFICATION 
To analyze the drug linking positions, the fractions of each HC positional isomer 
resulting from chymotrypsin digestion were collected. 1.0 M NaOH solution was added to 
neutralize the formic acid in the solution and the solution was further diluted with 100 mM 
tris buffer (pH 8.0) until ACN content was less than 20%. Then, 1.0 µg of trypsin was 
added to the solution and the peptides were digested with rapid enzyme digestion system 
at 37 ᵒC for 30 min. After digestion, formic acid was added (up to 0.5%) to quench the 
digestion. Isopropanol was also added (up to 20%) to prevent drug containing peptides 
from precipitation.  Then, 50 µL of digest was injected onto a Waters column (Acquity 
BEH C18, 1.7 µm, 2.1 x 50 mm, 130 Å) for separation. A 2.0 min isocratic elution with 
5% mobile phase B was used for desalting, and then the peptides were eluted from the 
column by increasing mobile phase B to 90% within 10.0 min.  MS analysis was performed 
on an AB Sciex 6600 QTOF HRMS with ESI ionization source, the detection was 
performed under positive ion mode in m/z from 150 to 2500 with heating temperature at 
500ᵒC and IS voltage at 5000 V.   
3. RESULTS AND DISCUSSION 
3.1. DRUG DISTRIBUTION ASSESSMENT 
PNGase F specifically cleaved the glycans and recovered the glycosylated 
asparagine back to aspartic acid thus eliminated the adverse effect of the glycans on the 
mass analysis. The further TCEP treatment reduced the interchain disulfide bonds to free 




drug, while the HC may be linked with 0-3 drugs. Each drug linkage contributed 
approximate 668 Da mass increase. Figure 2A showed the raw mass spectra of the 
deglycoslyated ADCs. The raw mass spectra were processed with BioPharmaView 




Figure 2. Subunit analysis of ADCs. Raw mass spectra (A) and deconvoluted mass 
spectra (B) of deglycosylated ADCs. 
 
The LC was detected with MW of 22936.33 Da and LC + 1 drug was detected at 
23603.68 Da with a mass increase of 667.35 Da. Likewise, HC species were detected with 
MW of 48949.02 Da, the HC drug linked species were detected at 49616.93 Da, 50285.73 
Da and 50953.01 Da with mass increase of 667.73 Da, 1336.71 Da, and 2003.99 Da, which 
matched well with the mass shift of 1, 2, and 3 drug molecules. The abundance of each 
species was calculated by their peak areas. 64.0% of the LC were linked with 1 drug and 
the remaining 36.0% were linked with no drug. 12.8%, 43.0%, 18%, and 26.3% of the HC 




The HRMS analysis of the ADCs at subunit level provided a feasible way to 
directly determine the drug distribution on each chain. In this analysis, it was assumed that 
all the LC or HC species with different drug linkage have same mass response. While, it is 
worth to note that the drug linkage and number of drug on the chains may have some effects 
on their mass response and thus might potentially compromise the accuracy of the method.  
3.2. IDES DIGESTION 
IdeS is an enzyme modified from Streptocoocus Pyogenes that is frequently used 
for the characterization and ADCs[26, 27]. It specifically cleaves human IgG1 antibody at 
the two consecutive glycine positions and produces Fab fragments with all the drug linking 
positions and Fc with glycans. The F(ab)2 fragments were further reduced by TCEP to 
generate free LC and Fd species. As a consequence, the LC species were linked with 0-1 
drug and Fd fragments were linked with 0-3 drugs.  
 
 




Figure 3 presented the deconvoluted mass spectra of IdeS treated ADCs. Fd was 
detected with MW of 25201.96 Da, Fd + 1 drug, Fd + 2 drugs, and Fd + 3 drugs species 
were detected at 25881.25 Da, 26550.29 Da and 27217.85 Da, which matched well with 
the mass shift of approximate 668 Da/drug. The detection of all the Fd species indicated 
that the drug linkage on the interchain cysteines didn't interfere with the function of IdeS. 
Meanwhile, all of the HC species disappeared after IdeS treatment, which indicated the 
complete digestion of the heavy chains regardless of the drug linkage.  
3.3. SEPARATION OF DRUG LINKING PEPTIDES 
In the subunit analysis, the distribution of different species and their abundances 
were easy to recognize. However, the HC +1 drug and HC +2 drugs species are actually 
mixture of 3 positional isomers and the individual isomers were not able to be monitored. 
The separations of those isomers were very difficult due to the long peptide and high 
similarity between the positional isomers, especially the hinge region position isomers 
which were only 2 amino acids apart. Instead of direct separation of those isomers, 
chymotrypsin that specifically cleave protein at the Y/W/F position was employed to digest 
the heavy chain to peptides for LC-MS analysis. The chymotrypsin digestion of HC results 
in peptide of HC_203-245 which preserved all the 3 drug linking positions that located at 
Cys_224, 230, and 233. Initially, direct chymotrypsin digestion of ADCs was performed 
using a typical protocol involving in 6.0 M urea denaturation, 5.0 mM TCEP reduction, 
25.0 mM iodoacetamide alkylation and chymotrypsin digestion (enzyme/substrate =1/50). 
However, the results showed very low intensity of 1 and 2 drug linked positional isomers. 




intensity comparing with the antibody digestion results. Therefore, the drug linkage on the 
interchain cysteines may potentially decreased the chymotrypsin cleavage efficiency at 
Phe_245 position. In this study, the ADCs were treated with IdeS first to completely digest 
the heavy chains at Gly_240 position, which eliminated the low digestion efficiency at 
Phe_245 position issue.  
 
 
Figure 4. Chromatography separation of heavy chain positional isomers. 
 
After IdeS digestion, the Fab fraction was further digested with chymotrypsin. The 
chymotrypsin digestion of the Fab fraction resulted in HC_203-240 peptide that was linked 
with 0-3 drugs. The relative short peptide enlarged the positional isomer differences and 
thus made it easier to separate them by using gradient elution, which was demonstrated in 
Figure 4. Peaks #1-3 that corresponding to HC_203-240 +1 drug positional isomers were 




calculated to be 87.2%, 6.5% and 6.3% based on their peak areas. Meanwhile, peaks #4-6 
that corresponding to the three HC_203-240 +2 drugs positional isomers were detected at 
7.11 min, 7.29 min, and 7.73 min with relative abundances of 14.3%, 20.2% and 65.5%. 
3.4. DRUG LINKING POSITIONS IDENTIFICATION 
To determine the peaks #1-6 drug linking positions, the analytes were fragmented 
and the fragment masses were compared with theoretical masses. However, no significant 
fragments with drug linkage were observed and thus unable to determine the drug linking 
positions. This may probably due to the long peptide sequence and resistance of 
fragmentation near drug linking positions. To solve this problem, the positional isomers, 
instead of direct fragmentation, were collected and further digested with trypsin. Trypsin 
digestion resulted in SCDK and THTCPPCPAPELLG peptides which preserved the drug 
linking positions. The relatively short peptides were used for drug linking position analysis.  
In the analysis of the positional isomers digests, peak #1 analyte digest was detected 
with SCDK + 1 drug and bear THTCPPCPAPELLG peptides, which indicated the drug 
linkage on Cys_224. Peak #6 analyte digest was detected with THTCPPCPAPELLG + 2 
drugs which confirmed the drug linkage on both Cys_230 and Cys_233. Peak #2 and Peak 
#4 analyte digests were both detected with THTCPPCPAPELLG +1 drug with retention 
time at 6.01 min (showed in Figure 5A). So, they have the same drug linkage position on 
the THTCPPCPAPELLG peptide. Similarly, the peak #3 and peak #5 analyte digests were 
also detected with THTCPPCPAPELLG +1 drug, but with different retention time at 6.12 
min (Figure 5B). The peak # 3 and peak #5 seemed having the same drug linking positions 






Figure 5. Identification of drug linking positions.  A &B: Peak # 4 and #5 digests were 
detected with THTCPPCPAPELLG + 1 drug at 6.01 and 6.12 min, respectively.  C: 
Fragmentation of RT= 6.01 min peak analyte.  D) Fragmentation of RT=6.12 min peak 
analyte.  
 
To determine the exact drug linking position, the two THTCPPCPAPELLG +1 
drug ions detected at RT=6.01 and 6.12 min were fragmented and the b type ions were used 
to identify the drug linking positions. These two peptides shared same mass fragments of 





Figure 5C demonstrated the fragments spectra of THTCPPCPAPELLG + 1 drug at 
RT=6.01 min. The detected m/z of 555.75, 604.28, 652.81, and 732.82Da matched well 
with the mass of b4 (+2), b5 (+2), b6 (+2) and b7 (+2) of the Cys_230 drug linked peptides, 
which confirmed drug linkage on Cys_230. Similarly, m/z of 500.17, 597.22, 694.28 and 
732.86 Da were detected in the spectra of THTCPPCPAPELLG +1 drug at RT=6.12 min 
(Figure 5D). Those masses matched well with the b4 (+1), b5 (+1), b6 (+1) and b7 (+1) of 
the Cys_233 linked peptides and the drug was identified to be linked on Cys_233. 
Meanwhile, peak # 4 and #5 digests were also detected with SCDK +1 drug which proved 
the other drug linkage on Cys_224.  The drug linking positions were summarized in Table 
1. 
 
Table 1. HC positional isomers drug linking positions. 
Peak # Number of drug Drug linking position 
#1 1 Cys_224 
#2 1 Cys_230 
#3 1 Cys_233 
#4 2 Cys_224, Cys_230 
#5 2 Cys_224, Cys_233 
#6 2 Cys_230. Cys_233 
 
3.5. DRUG DISTRIBUTION 
  Based on the subunit analysis and following by bottom up analysis. The drug 
distribution on LC and HC were calculated. Figure 6 demonstrated the processed data by 
combining the above stated analysis. 
In the study, an abnormal phenomenon was observed in the hinge region Cys_230 




region, 11.7% HC was linked with one drug on either Cys_230 or 233, and 38.0% of the 
HC was linked with 2 drugs at both of positions. It is quite abnormal that the percentage of 
one drug linkage is much lower than those of no drug linkage and 2 drugs linkage. Since 
the drug conjugation mainly depends on the reduction of the interchain disulfide bonds, the 
abnormal observation clearly indicates that the reduction of one pair of hinge region 
interchain disulfide favored the reduction of the other one. Similar phenomenon were 
observed in other interchain cysteine linked ADC[25, 26]. It was reported that the hinge 
region confirmation was changed for reduced monoclonal antibody due to the reduction of 









A novel mass spectrometry method was developed by combining subunit analysis 
and bottom up analysis for the characterization of the positional isomers of interchain 
cysteine linked ADCs. The subunit analysis provides effective way to evaluate the drug 
distribution on each chain, and the bottom up analysis using chymotrypsin digestion of 
IdeS treated ADCs produced relatively short peptides that preserved all the drug linking 
positions on the HC. The following LC/MS analysis separated those peptides and 
determined their relative abundances. The further MS/MS fragmentations of the analyte 
ions confirmed the drug linking positions. Overall, the positional isomers are well 
separated and their relative abundances was calculated. Since the method can provide 
accurate data on drug linking numbers and positions, it can be well used by researchers in 
ADC cancer drug discovery, development, and cancer treatment.   
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ABSTRACT 
Accurate determination of drug to antibody ratio (DAR) of interchain cysteine 
linked antibody drug conjugates (ADCs) is challenging. High resolution mass spectrometry 
(HRMS) analysis of the ADCs at intact or subunit level provides a feasible way to measure 
the DAR. However, the determined DAR is usually lower than the real DAR because of 
the ionization efficiency variation between different DAR species. In this research, we 
developed novel standard free HRMS method involving isotope labeled payload 
conjugation, protease digestion and LC/HRMS analysis for the accurate determination of 
DAR of interchain cysteine linked ADCs with cleavable or non-cleavable linkers. Isotope 
labeled payload conjugation eliminated the structural and chemical difference between 
different DAR species and ensured the drugs or payload containing peptides separation in 
the mass spectrometer. Papain digestion strategy works for ADCs with cleavable linkers 
showed the determined DAR of 3.79 and relative standard deviation (% RSD) of 0.48 




cleavable linkers showed determined DAR of 3.77 and %RSD of 0.86 (n=3). DAR 
determined by this method was consistent with DAR of the ADCs. This method will be 






Antibody drug conjugates (ADCs) are emerging therapeutic products specially 




selectively and provide better therapeutic advantage for patients[1,2]. ADC consists three 
components: monoclonal antibody (mAb), stable linker, and cytotoxic drug. mAb has high 
specificity and affinity toward the targets on cancer cell surfaces and leads to drug 
accumulation on the tumor site while minimizing cross-reactivity with normal tissues[3]. 
Stable linker connect drug and antibody together via covalent bonds and possess strong 
stability during circulation[4,5].Cytotoxic drugs have potent toxicity even at very low 
concentrations and have high stability and sufficient solubility in the aqueous 
environment[6,7].After administration, the ADCs circulate in the body and diffuse to the 
tumor site, then they recognize and bind to the tumor-associated antigen expressed on the 
surfaces of cancer cells by its antibody component and form ADC/antigen 
complexes[8]which was internalized into the cancer cells through receptor-mediated 
endocytosis[9,10].Thereafter, the internalized ADCs are degraded in lysosome and the 
active drugs are released into the cytoplasm. The cytotoxic drugs usually induce DNA 
damage or cell cycle arrest and therefore trigger cell apoptosis[11].The high selectivity 
make ADCs promising anticancer drugs for treatment of cancers. 
Among all the ADCs, interchain cysteine linked ADCs are the most popular one 
due to the controllable drug to antibody ratio (DAR) and heterogeneity[12]. It is estimated 
that approximate2/3 of all the ADCs under developing are interchain cysteine linked ADCs 
based on disclosed information[13].The interchain cysteine linked ADCs are manufactured 
by partial reduction of the 4 pairs of interchain disulfide bonds that are not critical for the 
structural stability while keeping the 12 intrachain disulfide bonds intact. The reduction 
generates 0-4 pairs of free thiols which are ready for conjugation with payloads (linker-




heterogeneous ADCs with DAR of 0, 2, 4, 6 and 8depending on the reduction condition of 
the interchain disulfide bonds[14,2].The DAR is an important parameter for the potential 
efficacy of ADCs and should be accurately determined[15]. 
Hydrophobic interaction chromatography (HIC)was often considered as gold 
standard for the analysis of the DAR of interchain cysteine linked ADCs[16], which was 
used to determine both the drug distribution and DAR. However, it required large amounts 
of ADCs (20 - 50 µg) and also required a high ADC concentration in samples. In recent 
years, high resolution mass (HRMS) analysis of ADCs at intact or subunit level provides 
a feasible way to determine the DAR[17-19].However, the DAR determined by the current 
HRMS methods is not accurate due to the ionization efficiency variation of different DAR 
species [17,20,21]. In HRMS analysis, the DAR was arbitrarily calculated based on the 
abundance of each species under the assumption that different DAR species have same 
ionization efficiencies[18].However, the ionization efficiency was naturally affected by the 
degree of hydrophobicity which was associated with the number of payload linked on the 
antibody[20]. It has been observed high DAR species has relatively lower ionization 
efficiency[17].Chen and coworkers compared the abundance of each DAR species 
measured by HRMS and HIC-UV/Vis method and found that HRMS method showed 
relatively low abundances of high DAR species comparing with HIC-UV/Vis results. 
Meanwhile, DAR of 2.9 determined HRMS was much lower than 3.4 determined by HIC 
method[17]. 
In this study, we developed novel HRMS methods for the accurate measurements 
of DAR. This method was standard free and require much less sample. Briefly, ADCs were 




(TCEP) to reduce the interchain disulfide bonds to free thiols. Thereafter, isotope labeled 
payloads were added to the beads suspension to alkylate the thiols. As a consequence, each 
antibody was linked with 8 payloads, either native or isotope labeled payloads. The ADCs 
were further digested with papain or trypsin& chymotrypsin mixture and the digests were 
analyzed by LC-HRMS. Free drugs or payload containing peptides were monitored to 
determine the DAR. 
2. EXPERIMENTAL SECTION 
2.1. RAGENTS AND MATERIALS 
Papain, Sodium phosphate dibasic, Sodium phosphate monobasic, trifluoroacetic 
acid (TFA), urea, L-cysteine and 0.5 M EDTA (pH 8.0) were obtained from Sigma Aldrich 
(St. Louis, MO). Protein A magnetic beads (30mg/mL), 1 M tris (pH 7.4), 1 M tris (pH 
8.0), TCEP and iodoacetamide were purchased from Thermo Fisher scientific (Rockford, 
IL).MC-VC-PAB-MMAE (vcMMAE) was purchased from Medkoo Biosciences 
(Morrisville, NC), trypsin and chymotrypsin were purchased from Promega corporation 
(Madison, WI),LC/MS grade acetonitrile (ACN),formic acid (FA)and LC/MS grade water 
were purchase from Fisher Scientific (Fair Lawn, NJ). Interchain cysteine linked ADCs 
employing NIST mAb and vcMMAE was synthesized in Frontage Laboratories (Exton, 
PA). DAR was determined to be DAR of 3.80 (See supplemental information). Isotope 
labeled payload (vcMMAE-d8) were provided by Frontage Laboratories (Exton, PA, See 




2.2. INSTRUMENTAL CONDITIONS 
Instrumental analysis was performed on LC/MS system employing Shimadzu 
LC30 for separation and AB Sciex 6600 QTOF for detection. Instrumental parameters were 
summarized in Table 1. 
 
Table 1. Instrumental parameters of LC/MS 
  LC/MS Method #1 LC/MS Method #2 
LC setting   
Column 
Waters Xbridge, Protein C4, 
3.5 µm, 2.1×50 mm 
Water Acquity BEH C18, 1.7 
µm, 2.1×50 mm 
Column 
Tempearture 
Ambient 45 ᵒC 
Mobile phase A 0.1% formic acid in water 
Mobile phase B 0.1% formic acid in ACN 
Flow rate 0.3 mL/min 
Gradient 
0-3 min:  5% B 0-1 min 30% B 
3-3.5 min:  5% B-90% B 1-5 min 30% B-90% B 
3.5-5.5 min 90% B 5-6.5min 90% B 
5.5-6 min 90% B-5% B 6.5-7 min 90% B-30% B 
6-8 min 5% B 7-9 min 30% B 
MS setting   
Curtain Gas 25 
Ionization Source ESI 
Temperature 500 ᵒC 
Detection mode Positive TOF MS 




Scan range m/z: 500-4000 m/z: 100-2500 
Dwell time 0.5 s 0.2 s 
Bin size 40 4 
2.3. VCMMAE-D8 CONJUGATION 
ADCs solution containing 0.5 µg of ADCs was mixed with20µL of protein A 




suspension to reach final TCEP concentration of 5.0mM. The beads suspension was 
incubated at room temperature for 30 min with agitation at 1000 rpm to prevent the beads 
precipitation. Thereafter, the beads were pulled down by using magnet and the supernatant 
was discarded. The beads were washed twice with conjugation buffer (50 mM phosphate, 
2.5 mM EDTA, pH 7.0).  
Prior conjugation, 50 µM of vcMMAE-d8 solution prepared in conjugation buffer 
was added to the beads. The beads suspension was incubated at 25 ̊C for 1 hr with agitation 
at 1000 rpm. While conjugation finishing, the beads were pulled down and the conjugation 
solution was discarded. The beads were washed with conjugation buffer twice and10% 
ACN once to remove the excessive vcMMAE-d8. Finally, the vcMMAE-d8 conjugated 
ADCs were eluted from the beads using 20 µL of 0.1% TFA in water and the eluted ADCs 
were neutralized with 2 µL of 1 M tris (pH 7.4). 
2.4. SUBUNIT ANALYSIS 
ADCs solution (before and after vcMMAE-d8 conjugation) were mixed with equal 
volume of 10 mM TCEP solution and the mixture was incubated for30 min. The subunit 
analysis was performed on a LC-HRMS system following LC/MS Method #1 as described 
in Instrumental conditions section. The raw mass spectra of the ADCs was processed with 
BioPharmaView software to obtain deconvoluted mass spectra. 
2.5. PAPAIN DIGESTION ANALYSIS 
Papain digestion was performed following manufacture’s protocol with minor 




ADC solution. L-cysteine was added to the mixture to5.0 mM. The mixture was incubated 
at 37ᵒC for 60min.Thereafter, formic acid was added to the mixture to a final concentration 
of 0.5% to quench the digestion. ACN was also added to the solution to a final 
concentration of 20% prevent the precipitation of MMAE/MMAE-d8. The digests were 
analyzed by LC/MS following LC/MS Method #1. MMAE and MMAE-d8 were monitored 
to calculate DAR. 
2.6. TRYPSIN & CHYMOTRYPSIN DIGESTION ANALYSIS 
The eluted ADCs were denatured with 20 µL of 10 M urea in the presence of 5 mM 
TCEP at 37 ᵒC for 1 hr. Then, iodoacetamide was added to 15 mM, and the mixture was 
incubated for 30 min in the dark. Prior digestion, digestion buffer containing 50 mM tris 
(pH 8.0) and 10% ACN was added to the mixture to dilute urea concentration to 1 M. 
Thereafter, 1 µg of trypsin and 0.1 µg of chymotrypsin were added to the mixture for 
digestion. The digestion was performed in a Rapid Enzyme Digestion System (400 W, 
37ᵒC) for 30min. Upon completion, formic acid was added to the mixture to a final 
concentration of 0.5% to quench the digestion. The digests were analyzed by LC/MS 
following LC/MS Method #2 as described in instrumental conditions section.  
3. RESULTS AND DISCUSSION 
3.1. VCMMAE-D8 CONJUGATION 
To accurately measure the DAR, conjugation of isotope labeled payloads to the 




conjugation is required. After isotope labeled payload conjugation, all different DAR 
species were transferred to DAR 8 species. Therefore, the structural physical and chemical 
differences between different DAR species were eliminated. Similarly, protease digestion 
efficiency variation between different DAR species in downstream protease digestion was 
also eliminated. While the mass differences between native and isotope labeled payloads 
made them still be able to be separated in mass spectrometer. Instead of using standard, 
isotope labeled payload conjugation provide a standard free way to determine the DAR. 
DAR may be determined by analyzing the percentage of native payload, which can be 
readily determined by bottom-up strategy taking the advantage of the same mass response 
factors of native and isotope labeled drugs as well as native and isotope labeled payload 
containing peptides.  
To link vcMMAE-d8 to the remaining interchain cysteine, the ADCs were first 
reduced with 5 mM TCEP to fully reduce all remaining interchain disulfide bonds to free 
reactive sulfhydryl groups. Prior conjugation, buffer exchanged was performed to remove 
the excessive TCEP. vcMMAE-d8 was added to the reduced ADCs to conjugate the free 
sulfhydryl groups with vcMMAE-d8. As a result, each antibody was linked with 8 
payloads, either vcMMAE or vcMMAE-d8. Figure 1A showed the deconvoluted mass 
spectra of the ADCs before vcMMAE conjugation. Light chain (LC) and LC +1 drug 
species were detected at 23,123 and 24,439 Da, respectively. Heavy chain (HC) with 0-3 
drug species were detected with 4 peak clusters between 51-56 K Da due to the complexity 
of the glycan attachment. While after vcMMAE-d8 conjugation, only LC+1 drug and HC 
+ 3 drugs species were detected (Figure 1 B). The missing of LC and HC with 0-2 drug 




linked with vcMMAE-d8. In general, it was difficult to achieve complete conjugation for 
all reduced sulfhydryl groups due to the low substrate concentrations.  However, protein A 
beads captured the all ADCs on the beads surface, which greatly enhanced the local ADCs 
concentrations and thus made it possible to reach complete conjugation within short time 
even though payload concentration was low. 
 
 
Figure 1. HRMS analysis of ADCs. A: Before isotope labeled payload conjugation.       
B: After isotope labeled payload conjugation. 
 
A mass shifts of about 5 Da were observed for LC+1 payload after vcMMAE 
conjugation, and similar mass shift was also observed in HC +3 payloads species. 
Theoretically, LC + vcMMAE-d8 and LC+ vcMMAE had mass difference of 8 Da and 
there should had two peaks in deconvoluted mass spectra. However, majority of their raw 
mass spectra overlapped and QTOF was unable to differentiate those subtle differences. 
As a consequence, they were considered as one species by the mass spectrometer and were 




enhanced mass spectra intensity between LC +vcMMAE and LC +vcMMAE-d8. 
Therefore, mass shift of about 5 Da was observed in the deconvoluted mass spectra. 
3.2. DAR DETERMINATION BY PAPAIN DIGESTION 
After isotope labeled payload conjugation, all the interchain cysteines were 
conjugated with either native or isotope labeled payloads. Then the ADCs were digested 
by papain in the presence of 5 mM cysteine. Papain effectively cleaved the linker at valine-
citrulline position and led to the release of PAB-MMAE or PAB-MMAE-d8 which 
spontaneously eliminated PAB part and therefore generated free MMAE or MMAE-d8113-
114.The papain digests were analyzed by LC-HRMS system following optimized method. 
MMAE and MMAE-d8, as shown in Figure 2A, were detected at 4.45 min.  
 
Table 2. DAR determination by papain digestion method. 
Sample Name 
Peak Area, 10^5 counts 
Calculated DAR 
MMAE MMAE-d8 
Sample #1 1.92 2.12 3.80 
Sample #2 2.56 2.84 3.79 




The chromatogram (Figure 2B) was extracted from the total ion chromatogram by 








AreaMMAE +  AreaMMAE−d8
 × 8 
Papain digestion of isotope labeled payload conjugated ADCs provided a feasible 
and quick way to determine the DAR. DAR was determined to be 3.79 which were very 
consistent with the DAR of 3.80 determined by UV/Vis method. Meanwhile, this method 
showed great precision, the relative standard deviation (%RSD) was only 0.48%. Good 
accuracy and precision were obtained. While, it is worth to note that the papain digestion 
relies on the cleavability of linker, therefore itis only applicable to interchain cysteine 
linked ADCs with cleavable valine-citrulline linkers.  
 
 
Figure 2. HPLC analysis of papain digest. A: Mass spectra of MMAE and MMAE-d8 
from papain digest. B: Chromatogram of papain digest. 
3.3. DAR DETERMINATION BY TRYPSIN & CHYMOTRYPSIN DIGESTION 
Different with papain digestion, DAR determination by trypsin & chymotrypsin 
digestion requires determination of DAR contribution of each drug linking site. Interchain 




located on heavy chain. Trypsin & chymotrypsin digestion of ADCs resulted in three 
payload containing peptides: GEC (LC_211-213) with one payload linkage, SCDK 
(HC_222-225) with 1 payload linkage and THTCPPCPAPELLGGSVF (HC_226-244) 
with two payloads linkage. The digests were analyzed by LC-HRMS and all the payloads 
containing peptides were detected.  
 
 
Figure 3. Mass spectra of payload containing peptides. A-C: Mass spectra of LC_211-213 
+ vcMMAE/vcMMAE-d8, HC_222-225 + vcMMAE/vcMMAE-d8 and HC_226-244 + 2 
vcMMAE/vcMMAE-d8; D: Mass distribution of HC_226-244+ 2vcMMAE/vcMMAE-
d8 species. 
 
Figure 3A-Cdemonstrated the mass spectra of the payload-containing peptides. 
LC_211-213 + vcMMAE/vcMMAE-d8 was detected at 3.50minwith m/z of 812.44/816.46 
Da (+2). Similarly, HC_222-225 + vcMMAE/vcMMAE-d8 was detected at 2.98 min with 




linked with two vcMMAE or vcMMAE + vcMMAE-d8 or two vcMMAE-d8. Those 




Figure 4. Chromatogram of trypsin & chymotrypsin digest. 
 
The mass spectra of two short peptides were well separated. However, mass spectra 
overlap was observed in HC_222-244 + 2 vcMMAE/vcMMAE-d8 species (Figure 3C) due 
to their large molecular weight and relatively small mass differences. Mass spectra 
crosstalk apparently will impair the accuracy of results and   therefore should be avoided 
while calculating DAR. The theoretical mass distributions (+4 state) of those species were 
plotted, as shown in Figure 4D, to determine the overlap condition of the mass spectra.  
The first four isotopic masses of each specie were observed with relative large mass 
crosstalk and therefore need to be avoided. The defined areas (dash line area) had very low 



















LC_211-213 3.30 3.02 NA 1.04 
3.81 HC_222-225 3.91 3.52 NA 1.05 
HC_226-244 5.39 1.89 7.55 1.71 
Sample #2 
LC_211-213 4.02 3.73 NA 1.04 
3.77 HC_222-225 4.31 3.99 NA 1.04 
HC_226-244 6.03 2.10 8.56 1.70 
Sample #3 
LC_211-213 3.04 2.84 NA 1.03 
3.74 HC_222-225 3.45 3.30 NA 1.02 




The Chromatogram, as shown in Figure 4, was extracted from total ion 
chromatogram by first isotopic mass or defined range. The peak areas were summarized in 
Table 3. The DAR contribution of each site was calculated by following formula: 
𝐷𝐴𝑅 = 2 ×
𝐴𝑀𝑀𝐴𝐸−𝑑8_1 + 2 × 𝐴𝑀𝑀𝐴𝐸−𝑑8_2
𝐴𝑀𝑀𝐴𝐸−𝑑8_0 + 𝐴𝑀𝑀𝐴𝐸−𝑑8_1 + 2 × 𝐴𝑀𝑀𝐴𝐸−𝑑8_2
 
where:  
AMMAE-d8_0=Peptide linked novcMMAE-d8 (only vcMMAE) 
AMMAE-d8_1= Peptide linked 1 vcMMAE-d8 
AMMAE-d8_2= Peptide linked 2 vcMMAE-d8 
The overall DAR was calculated based on the DAR contribution of each site. 
Overall DAR was calculated to be 3.77 which was consistent with the DAR of 3.80 
measured by UV/Vis method. The %RSD was determined to be 0.86%. Trypsin & 




worth to mention that the DAR contributions of Cys_213 on light chain and Cys_223 (HC) 
on heavy chain were consistent, which also demonstrated the complete conjugation of 
isotope labeled drugs to remaining interchain cysteines that without native payload linkage.  
In this study, we developed a novel standard free HRMS method for accurate 
determination of DAR of interchain cysteine linked ADCs. This method relied on 
combination of isotope labeled payload conjugation and protease digestion to determine 
the DAR and therefore should be also applicable to Thiomab cysteine linked antibody drug 
conjugates (TDCs) which are similar with interchain cysteine linked ADCs. In TDCs, the 
conjugation sites are specific and the payload linking mechanism is same as interchain 
cysteine linked ADCs, therefore it will also share all the advantages of this method. 
However, comparing with interchain cysteine linked ADCs, TDC are more simplified. 
TDCs only contain two drug linking positions. The standard is easy to obtain. Therefore, 
DAR determination by triple quadruple mass might be better regarding cost and detection 
limit.  
Isotope labeled payload was an important part in this study. While preparing isotope 
labeled payload, the heavy isotopes may be incorporated in linker portion or drug portion. 
The isotope position has no impact on the ADCs with non-cleavable linkers because 
payload still remain intact after protease digestion. While, the heavy isotope position will 
significantly affect the ADCs with cleavable linkers. Incorporation of heavy isotopes in the 
linker portion will deactivate papain digestion method which relied on the drugs to 
determine the DAR. It’s obvious that incorporation of heavy isotope in drug portion have 




payload might be more expensive than linker portion labeled payload since considering the 
price of drug and linker. 
In this study, bottom-up method was employed for determination of DAR after 
isotope labeled payload conjugation. It seemed middle-down analysis should be better than 
bottom-up method since the ionization efficiency variation between different DAR species 
were eliminated. However, the mass difference between native and isotope labeled payload 
was only 8 Da. While in deconvoluted mass spectra, LC and Fd peaks are quite wide, more 
than 20 Da. Obviously, 8 Da is not sufficient to guarantee separation of the native and 
isotope labeled payload linked species. Increase the mass difference between native and 
isotope labeled payload up to an extent of more than the peak width of LC and Fd might 
be a promising solution, but more costive should be expected.  
4. CONCLUSION 
Novel high-throughput mass methods were developed for the actually 
determination of the DAR of interchain cysteine linked ADC. The capture of ADCs on the 
protein A beads greatly enhanced the ADC concentration on the beads surface which made 
it possible for further conjugation. The conjugation of isotope labeled drug to the non-drug 
linking sites labeled the non-drug linkage site with isotope labeled drug. The latter subunit 
analysis of the isotope labeled drug conjugated ADC demonstrated the 1 drug linkage on 
light chain and 3 drug linkage on heavy chain proved completely conjugation to all the 
interchain cysteines. The labeled isotope drug not only eliminate the structural difference 




species at the following protease digestion. The papain digestion cleaved the linker and 
generate free MMAE/MMAE-d8 can be directly used for the determination of the DAR. 
The trypsin & chymotrypsin digestion cleaved the long peptides to short peptides, the drug 
containing peptides are monitored for the determination of DAR. Meanwhile, complete 
digestion is not required since no chemical and structural difference between each species. 
The 8 Da difference between native drug and isotope labeled drug was large enough for 
the mass separation of free drug and drug containing peptides. More importantly, this 
method works for both cleavable and non-cleavable linkers and are standard free. 
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32 µL of 10mM MC-VC-PABC-PNP linker solution was mixed with 48 µL of 10 
mM MMAE-d8, then HOBt and pyridine were added to final concentrations of 20µM and 
50µM, respectively. The mixture was incubated at room temperature for 48hrs with 
agitation. Upon completion, 320µL of water was added to the mixture and then was loaded 
on a C18 column for separation, the MC-VC-PAB-MMAE-d8 fraction was collected and 
then lyophilized to a powder form. The powder was dissolved with 10μL of DMSO and 
future diluted to 50 µM with 50 mM of phosphate buffer (pH 7.0). Figure 1 displayed mass 
spectra and chromatogram of purified vcMMAE. vcMMAE was detected with m/z of 
1324.7612 which was consistent with theoretical m/z of 1324.7865. 
 
 
Figure 1. Purified vcMMAE-d8 confirmation. (A) Mass spectra of purified vcMMAE-d8. 






500µg of antibody was dissolved in 100µL of PB-E (50mM phosphate, 2.5mM 
EDTA, pH7.0), contain 186 µM of TCEP and incubated under room temperature for 2 hr 
for reduction, afterwards, 100µL of 200µM MC-VC-PAB-MMAE prepared in PBE was 
added to the mixture and incubate for 1hr under RT. The synthesized ADCs were purified 
by passing through PD-10 desalting column to remove the excessive vcMMAE. The 
purified ADCs were lyophilized to dry and reconstituted to with PBS to 1 mg/mL. 
 
DAR MEASUREMENT BY UV/VIS SPECTROMETRY 
The DAR was measured by UV/Vis method. Briefly, the absorbance was measured 
at 248 nm and 280 nm. The DAR was calculated based on reported absorbance coefficient.  
 
Table1. DAR measurement by UV/Vis method 
  
mAb VC-MMAE 
248 nm 280 nm 248 nm 280 nm 
ε, M-1*cm-1 9.91E+04 2.11E+05 1.59E+04 1.50E+03 




248 nm 280 nm 
#1 0.333 0.454 0.733 3.78 
#2 0.341 0.462 0.738 3.85 
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ABSTRACT 
Non-small cell lung cancer is the major type of lung cancer that cause thousands of 
deaths each year. Most patients were diagnosed at later stages where chemotherapy was 
the dominant treatment therapy. However, chemotherapy had severe side effects and 
limited benefit on treatment due to its non-selectivity. Developing new drug to improve the 
selectivity of the drug was desired. Here we report the design and synthesis of new antibody 
drug conjugates for specially targeting of EGFR overexpressed the lung cancer. Cetuximab 
that has high affinity toward EGFR was selected as drug carrier, potent toxic Staurosporine 
was chosen as the cytotoxic agent to kill cells. A cleavable peptide linker was employed to 
link the Cetuximab and Staurosporine. The ADCs were successfully synthesized and the 
anticancer activity was evaluated on human A549 cells. Compared to Cetuximab, 





Lung cancers is the leading causes of cancer related death in the United States. It is 
estimated about 220,000 of people are diagnosed with lung cancer and 158,000 patients 
die of it.[1] Non-small cell lung cancer (NSCLC) that accounts for 80% of the all the lung 
cancer patients was the major lung cancer type.[2] The two year survival rate is only 10%-
20%.[3] For NSCLC, surgical resection that remove the tumor tissue was the desired 
therapy.[4] Unfortunately, most of the NSCLC patients were diagnosed at advanced stage 
where surgery was limited and chemotherapy became primary therapy. Chemotherapy 
employing non-selective toxic agent for treatment showed systemic toxicity to host and 
narrow therapeutic window.[5] Meanwhile, resistance was developed in many patients. 
Clearly, developing target therapies to overcome the drawbacks of chemotherapies was 
desired for the treatment of NSCLC.  
Antibody-drug conjugates (ADCs) were an emerging target therapeutics specially 
designed for the treatment of cancer. Different with traditional drugs, ADCs were actually 
pro-drugs which have 3 components: monoclonal antibody (mAb), stable linker and potent 
cytotoxic anti-cancer agents. [6] The anti-cancer agents were conjugated the antibody via 
stable linkers. Monoclonal antibody specifically recognize the target expressed on tumor 
cell surface and bind to it. The following receptor  mediated endocytosis internalized the 
ADCs into the cell where the anti-cancer agents were released to kill cancer cells from 
inside.[7] ADCs selectively deliver the anti-cancer agents to cancers cells and has none or 




compared with the conventional chemotherapy and thus showed great promising on 
treatment of NSCLC. 
EGFR is a tyrosine receptor on cell surface related with cellular proliferation 
regulation, differentiation, and cell survival. [8] It was reported one of the most significant 
oncogenes of cancer. [9] In NSCLC, EGFR was frequently overexpressed. Its aberrant 
expression induces abnormal abundant signaling transduction to the nucleus affecting cell 
cycle regulators, inflammatory agents and indirectly disorganizing the apoptotic pathway. 
[8] Overexpression of EGFR in NSCLC is correlated with a high metastatic rate, poor 
tumor differentiation, and a high rate of tumor growth [10]. In normal cells, the expression 
of EGFR was low. [11]  While in some NSCLC, over expression of EGFR were detected. 
In a study, 70% specimens exhibited and 3+ EGFR staining in ICH assay. [12]. The big 
difference of EGFR expression makes EGFR a good target for developing of ADCs. 
Cetuximab is an anti-EGFR mouse/human chimerical mAb developed for the 
treatment of cancer. It had been explored in the last decades on the treatment of 
NSCLC.[13] However, limited therapeutic advantage was observed mainly due to the 
acquired resistance. The reason involved in the mutation of the EGFR and the development 
of alternative signaling pathway by adapting to ERBB2 pathway.[14, 15] Dysregulation of 
EGFR internalization/degradation and subsequent EGFR-dependent activation of HER2 
and HER3 was also reported as part of the reason.[16] Even though it showed limited 
therapeutic efficacy, it showed great affinity to the EGFR with Kd of 87 pM and strongly 





Staurosporine (STS), a potent toxic microbial alkaloid, was employed as anti-
cancer agent to trigger cell death.  It has high affinity to cyclin-dependent kinase 2 (CDK2) 
with IC 50 of 3.2 nM.[18] It binds to the ATP binding site and mimic the hydrogen 
bonds made by the adenine moiety of ATP.[19] Once bound, it forms hydrogen bonds with 
Glu-81, Leu-83, Asp-86 and Gln-131. The binding of STS to CDK2 forms a very 
hydrophobic environment and become inaccessible for the aqueous solvents which made 
it difficult for detachment of STS from CDK2.[20] Besides that, STS has high affinity to 
the PKCs and CDK2 with IC50 of 2.7 nM which are crucial for the cell survival.[21] 
Treatment of cells with STS induced the cell cycle arrested at G1/G2 phase and further 
induced apoptosis.[22] Staurosporine was a promising anti-cancer agent for the ADCs.  
In this study, a new ADC (Cetuximab-STS) was designed to target NSCLC with 
EGFR over expression.  Cetuximab was employed as carrier and STS was employed as 
anti-cancer agent to trigger cell death. A cleavable peptide linker was employed to link the 
cytotoxic Staurosporine to the Cetuximab. The ADCs were synthesized and characterized 
by HRMS. The anti-cancer activity was investigated on human lung cancer A549 cells. 
2. EXPERIMENTAL SECTION 
2.1. REAGENTS AND MATERIALS 
Sodium phosphate dibasic, Sodium phosphate monobasic and 0.5 M EDTA (ph 
8.0), PBS, cell Counting kit (WST-8), Hydroxybenzotriazole (HOBt) and pyridine were 
obtained from Sigma Aldrich (St. Louis, MO). Cetuximab was purchased from Selleck 




p-nitrophenyl carbonate (MC-VC-PABC-PNP) and staurosporine were obtained from 
MedChemExpress LLC (Monmouth Junction, NJ). A549 cells,  F12-K medium, Fatal 
bovine serum, Penicillin-Streptomycin Solution,  0.025% trypsin solution were purchased 
from ATCC (Manassas, VA), 1 M tris (pH 7.4), 1 M tris (pH 8.0), tris(2-
carboxyethyl)phosphine (TCEP) were purchased from Thermo Fisher scientific (Rockford, 
IL). LC-MS grade acetonitrile (ACN), formic acid and water were purchase from Fisher 
Scientific (Fair Lawn, NJ). PD 10 desalting column was purchased from GE Healthcare 
Life Science (Pittsburgh, PA) 
2.2. SYNTHESIS OF VCSTS 
MC-VC-PABC-PNP and staurosporine were dissolved in DMF at final 
concentration of 5mM and 7.5 mM, respectively. HOBt and pyridine were added to the 
mixture to final concentration of 20 µM and 50 µM. The mixture was incubated at room 
temperature for 48 hr with agitation. Upon finish, the mixture was loaded on a C18 column, 
water and ACN was used as mobile phase for the separation. The vcSTS fraction was 
collected and lyophilized to dry. The vcSTS was dissolved in DMSO to get final 
concentration of 1 mM. 
2.3. CETUXIMAB-STS SYNTHESIS 
1 mg of Cetuximab solution was mixed with 5 mL of protein A beads (30 mg/mL) 
and incubated for 30 min with agitation. TCEP was added to the mixture to final 
concentration of 0.1 mM and keep incubate for 30 min. The beads were pull down with 




to remove the excessive TCEP. The beads were suspended in 5 mL of conjugation buffer. 
vcSTS was added to the beads suspension to a final concentration of 15 µM. The beads 
suspension was incubated at RT for 1 hr with agitation. While finish, the beads were pull 
down with magnet and washed three times with conjugation buffer. The ADCs were eluted 
from beads by 2.5 mL of 10 mM phosphate buffer (pH 2.8). The eluted ADCs were passed 
through a PD 10 desalting column equilibrated with 10 mM of phosphate buffer (pH 7.0). 
The ADCs solution was filtered through 0.22 µm PVDF filter under sterile condition and 
store in sterile container. 
2.4. CETUXIMAB-STS CHARACTERIZATION 
To reduce the heterogeneity, 10 µg ADCs were mixed with 10 unit of IdeS and the 
mixture was incubated at 37 ᵒC for 1 hr. TCEP was added to the mixture to final 
concentration of 5 mM and incubate at RT for 30 min. Afterwards, equal volume of 20% 
ACN in 50 mM tris (pH 7.4) was added to the mixture. The DAR analysis was performed 
on LC-QTOF system with water containing 0.1% formic acid as mobile phase A and ACN 
containing 0.1% formic acid as mobile phase B. The digest was loaded on a C4 column 
(Waters BEH Protein, C4, 3.5 µm, 2.1 x 100 mm, 300 angstroms), a 2 min isocratic elution 
with 5% mobile phase was applied for online desalting. The analytes were eluted from the 
column by increase the % B to 75% within 0.5 min and kept at 75% B for another 2 min. 
A Sciex 6600 QTOF mass spectrometer was coupled with the LC system for data 
acquisition. The mass spectrometer was operated in positive mode with mass range of m/z 




native mass spectra of the analytes was process with BioPharmaView software to obtain 
deconvolution mass spectra. 
2.5. CELL CULTURE 
A549 cells were cultured in F12-K medium containing 10% fetal bovine serum and 
antibiotic–antimycotic agent at 37 °C in a humidified incubator with 5% CO2/air. Cells 
were trypsinized and harvested at 90% confluence. Cells were suspended in medium for 
further assay.  
2.6. CELL VIABILITY ASSAY 
A549 cells were inoculated in 96 well plate at 5 × 104 cells/well in F12-K medium. 
The supernatant was removed after incubation at 37 ᵒC and 5% CO2 for 24 hr. 100 µL of 
Cetuximab/Cetuximab-STS solution prepared in F12K medium at 0, 1 nM, 5 nM, 10 nM, 
0.25 nM, 0.5 nM and 1 nM were added to the wells. The cells were incubated at 37°C in 
5% CO2 for 72 hr. After Cetuximab/Cetuximab-STS treatment, 10 μL of WST-8 solution 
was added into each well and mixed well. The cells were incubated at 37°C for 45 min. 
After incubation, the absorbance (A) at λ = 460 nm was read on a plate reader. 
3. RESULTS AND DISCUSSION 
3.1. SYNTHESIS OF VCSTS 
After 48 hr reaction, vcSTS, as shown in Figure 1, was successfully synthesized.  
vcSTS was purified by LC and pure vcSTS was obtained. The synthesized vcSTS was 




matched well with theoretical mass. Meanwhile, the compound was fragmented under CID 
mode. The fragments were matched well with the theoretical mass as shown in Figure 1.  
 
 
Figure 1. Structure of vcSTS and MS characterization of vc STS. 
 
3.2. CETUXIMAB-STS CHARACTERIZATION 
Cetuximab-STS was a heterogeneous mixture showed greatly complexity. 
Cetuximab has 4 glycosylation located on heavy chain. Two of them located on the Fc 
(Asn_297), the other two located on the Fd (Asn_88). The great difference on the glycan 
forms plus the drug linking number difference made it challenging for the drug to antibody 




difficulties on the interpretation of the mass spectra. Deglycoyslation by PNGase F 
successfully removed the glycan attached on Fc under native condition. However, the 
glycan on the Fd was not removed under native condition (See supplemental information) 
which probably due to the position hindrance made it inaccessible to the enzyme. While 
the complexity of the glycan on the Fd still made it difficult to interpret the mass spectra. 
  
 
Figure 2. Characterization of Cetuximab-STS. A: Deconvoluted mass spectra of light 
chain and Fc species. B: Deconvoluted mass spectra of Fd species. 
 
 
Instead of analyze ADCs at intact level, IdeS treatment of the ADCs successfully 
cleaved the ADCs at hinge region and thus removed the Fc portion and reduced the 
heterogeneity. The further treatment of TCEP reduced the interchain disulfide bonds and 
generated LC and Fd species that carrying all the drugs was subjected for LC-HRMS 
analysis. Figure 2A showed the deconvolution mass spectra of the ADCs fragments. The 
light chain species were detected at 23424 Da and 24488 Da, with mass difference of 1064 
Da which matched well with the MW of the vcSTS.  Fcs were detected with three major 
forms with MW of 25232, 25394 and 25555 Da with mass shift of 1443, 1605 and 1766 




matched well with the mass of G0F, G1F and G2F. Fd species were detected with peak 
clusters between 27 KDa and 31KDa. Fd species showed complicated mass spectra due to 
the glycan on the Asn_88 (Figure 2B). Three major and four minor form of Fds were 
detected. However, due to the low abundance of the four minor forms, the DAR was 
estimated by three major forms. Table 1 displayed the deconvolution DAR calculation of 
the ADCs. The DAR was estimated to be 4.0. 
 











111051 19% 0 27510 59896 
27803 24496 
Fd + 1 drug 
28285 44460 
184363 31% 0.62 28576 108179 
28868 31725 
Fd + 2 drugs 
29350 56814 
188551 32% 1.28 29641 84469 
29932 47269 
Fd + 3 drugs 
30415 14357 
106362 18% 1.08 30706 84606 
30996 7400 
LC 23423 1765877 
3761118 
47% 0 
LC + 1 drug 24488 1995241 53% 1.06 
DAR 4.04 
 
3.3. CETUXIMAB-STS TOXICITY 
The toxicity of Cetuximab-STS was investigated on A549 cell which has moderate 
EGFR expression. Cetuximab was used as positive controls. The Cetuximab and 
Cetuximab-STS was prepared in cell culture media at concentration of 0.0334, 0.0667, 0.2, 





   Figure 3. Toxicity of Cetuximab and Cetuximab-Staurosporine to A549 cells. 
 
Within the test range, Cetuximab didn't show significant toxicity towards A549 
cells, which was consistent with published data. Cetuximab-STS didn't show toxicity 
towards A549 cells at lower concentration. Its toxicity increased along with the increase of 
the ADCs dose concentration. At higher concentration, Cetuximab-STS significant 
induced toxicity to the A549 cells at 0.667 and 1 µM comparing with Cetuximab. Higher 
concentration supposed to have higher toxicity, however, higher concentration tends to 
aggregate probably due to the high hydrophobicity of the payload which has poor solubility 

































Cetuximab –Staurosporine, a new ADC targeting EGFR, was successfully designed 
and synthesized. A cleavable linker was employed to link the Staurosporine and 
Cetuximab. Instead of using in solution conjugation, on beads conjugation method was 
employed for the manufacture of ADCs. vcSTS was very hydrophobic and therefore had 
very poor solubility in aqueous phase. Its solubility is less than 10 µM which made it 
difficult for conjugation. Protein A beads captured the antibodies on the surfaces of the 
beads and the concentration of antibodies at the surface of beads was greatly enhanced. As 
a consequence, the conjugation finished within 1 hour despite the low concentration of 
payload. Cetuximab contains 4 glycans and two of the glycans on the Fab were resistant to 
the PNGase F digestion probably due to the structural hindrance. Therefore, the 
synthesized ADCs were characterized by middle down strategy considering the complexity 
of the glycan. All the fragments were detected, and the DAR was calculated to be 4.0 based 
on the abundance of each species. The anticancer toxicity of Cetuximab-Staurosporine was 
evaluated on human A549 cells which had moderate expression of EGFR. Cetuximab was 
used as positive control. Comparing with Cetuximab, Cetuximab showed significant 
toxicity toward A549 cells. The EC 50 was calculated to be 2.6 µM. The EC50 was 
relatively high probably due to the high hydrophobicity induced by the payload. The ADCs 
might aggregate and lower the anticancer effectiveness. In summary, Cetuximab-
Staurosporine was successfully synthesized and significant anticancer toxicity was 
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2. CONCLUSIONS  
In this work, novel high resolution mass spectrometry method was developed for 
the characterization of heterogeneity of the interchain cysteine linked ADCs. In HRMS 
analysis of the reduced subunit of the ADCs, all the subunits were detected, therefore it 
provided the overall drug distribution information. Latter bottom up strategy was employed 
to determine the positional isomer distribution as well as to identify the drug linking 
positons. ADC were well characterized by combining subunit analysis and bottom up 
analysis.  
In addition, novel method was also developed to accurately determine the DAR. 
Isotope labeled payload conjugation of the remaining interchain cysteines transferred 
different DAR species to DAR 8 species. Therefore, variations of the ionization efficiency 
and downstream protease digestion were eliminated. Papain or trypsin & chymotrypsin 
digestion provided feasible ways to determine the DAR of interchain cysteine linked ADCs 
with cleavable and non-cleavable linkers. The results matched well with the DAR 
determined by standard method. Good accuracy and precision was achieved. 
In the last part of the research, Cetuximab was designed and successfully 
synthesized employing Cetuximab as drug carrier and Staurosporine as cytotoxic agents. 
The Synthesized ADCs were characterized by HRMS. The DAR of the ADCs was 
determined and the anticancer effect was evaluated on A549 cells. The results indicated 
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